Role of macrophage inflammatory protein (MIP)-1α/CCL3 in leukemogenesis

Molecular and Cellular Oncology

Volumn 1, Issue 1, 2014, Pages

  Baba, Tomohisa ^a   Mukaida, Naofumi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

chemokine; leukemia; leukemia initiating cell; microenvironment; MIP 1 CCL3

Indexed keywords

EID: 85011268803     PISSN: None     EISSN: 23723556     Source Type: Journal    
DOI: 10.4161/mco.29899     Document Type: Review

References (46)

1. Davatelis G, Tekamp-Olson P, Wolpe SD, Hermsen K, Luedke C, Gallegos C, Coit D, Merryweather J, Cerami A. Cloning and characterization of a cDNA for murine macrophage inflammatory protein (MIP), a novel monokine with inflammatory and chemokinetic properties. J Exp Med 1988; 167:1939 - 44; http://dx.doi.org/10.1084/jem.167.6.1939; PMID: 3290382
2. Cook DN. The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukoc Biol 1996; 59:61 - 6; PMID: 8558069
3. Toksöz D, Dexter TM, Lord BI, Wright EG, Lajtha LG. The regulation of hemopoiesis in long-term bone marrow cultures. II. Stimulation and inhibition of stem cell proliferation. Blood 1980; 55:931 - 6; PMID: 7378583
4. Lord BI, Mori KJ, Wright EG, Lajtha LG. Inhibitor of stem cell proliferation in normal bone marrow. Br J Haematol 1976; 34:441 - 5; http://dx.doi.org/10.1111/j.1365-2141.1976.tb03590.x; PMID: 990183
5. Graham GJ, Wright EG, Hewick R, Wolpe SD, Wilkie NM, Donaldson D, Lorimore S, Pragnell IB. Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature 1990; 344:442 - 4; http://dx.doi.org/10.1038/344442a0; PMID: 2320111
6. Lord BI, Dexter TM, Clements JM, Hunter MA, Gearing AJ. Macrophage-inflammatory protein protects multipotent hematopoietic cells from the cytotoxic effects of hydroxyurea in vivo. Blood 1992; 79:2605 - 9; PMID: 1586712
7. Broxmeyer HE, Sherry B, Lu L, Cooper S, Oh KO, Tekamp-Olson P, Kwon BS, Cerami A. Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells. Blood 1990; 76:1110 - 6; PMID: 2205307
8. Broxmeyer HE, Sherry B, Lu L, Cooper S, Carow C, Wolpe SD, Cerami A. Myelopoietic enhancing effects of murine macrophage inflammatory proteins 1 and 2 on colony formation in vitro by murine and human bone marrow granulocyte/macrophage progenitor cells. J Exp Med 1989; 170:1583 - 94; http://dx.doi.org/10.1084/jem.170.5.1583; PMID: 2478652
9. Verfaillie CM, Catanzarro PM, Li WN. Macrophage inflammatory protein 1 alpha, interleukin 3 and diffusible marrow stromal factors maintain human hematopoietic stem cells for at least eight weeks in vitro. J Exp Med 1994; 179:643 - 9; http://dx.doi.org/10.1084/jem.179.2.643; PMID: 8294873
10. Dunlop DJ, Wright EG, Lorimore S, Graham GJ, Holyoake T, Kerr DJ, Wolpe SD, Pragnell IB. Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1 alpha in vivo. Blood 1992; 79:2221 - 5; PMID: 1571537
11. Lord BI, Woolford LB, Wood LM, Czaplewski LG, McCourt M, Hunter MG, Edwards RM. Mobilization of early hematopoietic progenitor cells with BB-10010: a genetically engineered variant of human macrophage inflammatory protein-1 alpha. Blood 1995; 85:3412 - 5; PMID: 7540061
12. Broxmeyer HE, Orazi A, Hague NL, Sledge GW, Jr., Rasmussen H, Gordon MS. Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer. Blood Cells Mol Dis 1998; 24:14 - 30; http://dx.doi.org/10.1006/bcmd.1998.0167; PMID: 9516378
13. Cook DN, Beck MA, Coffman TM, Kirby SL, Sheridan JF, Pragnell IB, Smithies O. Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science 1995; 269:1583 - 5; http://dx.doi.org/10.1126/science.7667639; PMID: 7667639
14. Nibbs RJ, Wylie SM, Yang J, Landau NR, Graham GJ. Cloning and characterization of a novel promiscuous human beta-chemokine receptor D6. J Biol Chem 1997; 272:32078 - 83; http://dx.doi.org/10.1074/jbc.272.51.32078; PMID: 9405404
15. Broxmeyer HE, Cooper S, Hangoc G, Gao JL, Murphy PM. Dominant myelopoietic effector functions mediated by chemokine receptor CCR1. J Exp Med 1999; 189:1987 - 92; http://dx.doi.org/10.1084/jem.189.12.1987; PMID: 10377195
16. Ottersbach K, Cook DN, Kuziel WA, Humbles A, Lu B, Gerard C, Proudfoot AE, Graham GJ. Macrophage inflammatory protein-1alpha uses a novel receptor for primitive hemopoietic cell inhibition. Blood 2001; 98:3476 - 8; http://dx.doi.org/10.1182/blood.V98.12.3476; PMID: 11719391
17. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730 - 7; http://dx.doi.org/10.1038/nm0797-730; PMID: 9212098
18. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, Woll P, Mead A, Alford KA, Rout R, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011; 19:138 - 52; http://dx.doi.org/10.1016/j.ccr.2010.12.012; PMID: 21251617
19. Holtz M, Forman SJ, Bhatia R. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res 2007; 67:1113 - 20; http://dx.doi.org/10.1158/0008-5472.CAN-06-2014; PMID: 17283145
20. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005; 5:311 - 21; http://dx.doi.org/10.1038/nrc1592; PMID: 15803157
21. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25:1315 - 21; http://dx.doi.org/10.1038/nbt1350; PMID: 17952057
22. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105 - 11; http://dx.doi.org/10.1038/35102167; PMID: 11689955
23. Scadden DT. Cancer stem cells refined. Nat Immunol 2004; 5:701 - 3; http://dx.doi.org/10.1038/ni0704-701; PMID: 15224098
24. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005; 15:494 - 501; http://dx.doi.org/10.1016/j.tcb.2005.07.004; PMID: 16084092
25. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340:1330 - 40; http://dx.doi.org/10.1056/NEJM199904293401706; PMID: 10219069
26. Koschmieder S, Göttgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL, Dayaram T, Geary K, Green AR, Tenen DG, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005; 105:324 - 34; http://dx.doi.org/10.1182/blood-2003-12-4369; PMID: 15331442
27. Chasty RC, Lucas GS, Owen-Lynch PJ, Pierce A, Whetton AD. Macrophage inflammatory protein-1 alpha receptors are present on cells enriched for CD34 expression from patients with chronic myeloid leukemia. Blood 1995; 86:4270 - 7; PMID: 7492787
28. Dürig J, Testa NG, Lord BI, Kasper C, Chang J, Telford N, Dexter TM, Heyworth CM. Characterisation of the differential response of normal and CML haemopoietic progenitor cells to macrophage inflammatory protein-1alpha. Leukemia 1999; 13:2012 - 22; http://dx.doi.org/10.1038/sj.leu.2401610; PMID: 10602423
29. Eaves CJ, Cashman JD, Wolpe SD, Eaves AC. Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells. Proc Natl Acad Sci U S A 1993; 90:12015 - 9; http://dx.doi.org/10.1073/pnas.90.24.12015; PMID: 8265663
30. Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU, Hair A, Holyoake TL, Huettner C, Bhatia R. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 2012; 21:577 - 92; http://dx.doi.org/10.1016/j.ccr.2012.02.018; PMID: 22516264
31. Wark G, Heyworth CM, Spooncer E, Czaplewski L, Francis JM, Dexter TM, Whetton AD. Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha. Oncogene 1998; 16:1319 - 24; http://dx.doi.org/10.1038/sj.onc.1201914; PMID: 9546433
32. Baba T, Naka K, Morishita S, Komatsu N, Hirao A, Mukaida N. MIP-1α/CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia. J Exp Med 2013; 210:2661 - 73; http://dx.doi.org/10.1084/jem.20130112; PMID: 24166712
33. Nicholls SE, Lucas G, Graham GJ, Russell NH, Mottram R, Whetton AD, Buckle AM. Macrophage-inflammatory protein-1alpha receptor expression on normal and chronic myeloid leukemia CD34+ cells. J Immunol 1999; 162:6191 - 9; PMID: 10229864
34. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, Lydon NB. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56:100 - 4; PMID: 8548747
35. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561 - 6; http://dx.doi.org/10.1038/nm0596-561; PMID: 8616716
36. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031 - 7; http://dx.doi.org/10.1056/NEJM200104053441401; PMID: 11287972
37. Schepers K, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, Wagers AJ, Hsiao EC, Passegué E. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 2013; 13:285 - 99; http://dx.doi.org/10.1016/j.stem.2013.06.009; PMID: 23850243
38. Owen-Lynch PJ, Adams JA, Brereton ML, Czaplewski LG, Whetton AD, Yin JA. The effect of the chemokine rhMIP-1 alpha, and a non-aggregating variant BB-10010, on blast cells from patients with acute myeloid leukaemia. Br J Haematol 1996; 95:77 - 84; http://dx.doi.org/10.1046/j.1365-2141.1996.7312349.x; PMID: 8857942
39. Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, Calvi LM. Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood 2012; 119:540 - 50; http://dx.doi.org/10.1182/blood-2011-04-348151; PMID: 21957195
40. Argiropoulos B, Palmqvist L, Yung E, Kuchenbauer F, Heuser M, Sly LM, Wan A, Krystal G, Humphries RK. Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3. Exp Hematol 2008; 36:845 - 59; http://dx.doi.org/10.1016/j.exphem.2008.02.011; PMID: 18375036
41. Burger JA, Quiroga MP, Hartmann E, Bürkle A, Wierda WG, Keating MJ, Rosenwald A. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009; 113:3050 - 8; http://dx.doi.org/10.1182/blood-2008-07-170415; PMID: 19074730
42. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, et al. CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011; 117:1662 - 9; http://dx.doi.org/10.1182/blood-2010-09-307249; PMID: 21115978
43. Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D, Bossi F, Lorenzon D, Degan M, Rossi FM, et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009; 69:4001 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-08-4173; PMID: 19383907
44. Matsumoto K, Murao K, Imachi H, Nishiuchi T, Cao W, Yu X, Li J, Ahmed RA, Iwama H, Kobayashi R, et al. The role of calcium/calmodulin-dependent protein kinase cascade on MIP-1alpha gene expression of ATL cells. Exp Hematol 2008; 36:390 - 400; http://dx.doi.org/10.1016/j.exphem.2007.11.013; PMID: 18249060
45. Lentzsch S, Gries M, Janz M, Bargou R, Dörken B, Mapara MY. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003; 101:3568 - 73; http://dx.doi.org/10.1182/blood-2002-08-2383; PMID: 12506012
46. Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007; 110:3744 - 52; http://dx.doi.org/10.1182/blood-2007-05-093294; PMID: 17715391